conventional synthetic DMARDs
GPTKB entity
Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:alternativeTo |
gptkb:biologic_DMARDs
gptkb:targeted_synthetic_DMARDs |
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:contraindication |
pregnancy
|
| gptkbp:firstLineTherapyFor |
rheumatoid arthritis
|
| https://www.w3.org/2000/01/rdf-schema#label |
conventional synthetic DMARDs
|
| gptkbp:includesDrug |
gptkb:methotrexate
gptkb:leflunomide gptkb:sulfasalazine hydroxychloroquine |
| gptkbp:mechanismOfAction |
immunosuppression
|
| gptkbp:monitors |
liver function tests
blood counts |
| gptkbp:onset |
weeks to months
|
| gptkbp:routeOfAdministration |
oral
parenteral |
| gptkbp:sideEffect |
rash
hepatotoxicity gastrointestinal upset bone marrow suppression |
| gptkbp:usedFor |
gptkb:systemic_lupus_erythematosus
gptkb:psoriatic_arthritis rheumatoid arthritis |
| gptkbp:bfsParent |
gptkb:DMARDs
|
| gptkbp:bfsLayer |
7
|